Medicare’s new obesity drug coverage could be a turning point for patients

For years, the price tag did the talking. A doctor could recommend a GLP-1 drug, a patient could understand the medical reason, and then the pharmacy counter could end the conversation with a number too high to carry home. Now Medicare is testing a very different number: $50.

Starting July 1, 2026, the Medicare GLP-1 Bridge gives eligible Part D beneficiaries access to selected obesity drugs, including Foundayo, Wegovy, and Zepbound KwikPen, for a $50 monthly copay through December 31, 2027.

CMS calls it a short-term demonstration, not a permanent benefit. For patients who have spent years being told obesity is a personal failure, the shift may feel bigger than a prescription. It may feel like recognition.

What Medicare is changing

The new program does not open the door to every weight-loss drug for every Medicare enrollee. It creates a temporary national pathway for certain people with Medicare drug coverage, including standalone Part D plans, Medicare Advantage drug plans, Special Needs Plans, employer or union waiver plans, and the LI NET program.

Medicare.gov lists three covered drug options: Foundayo tablets, Wegovy injections or tablets, and Zepbound KwikPen, while CMS says the $50 copay sits outside the usual Part D payment system.

That detail matters because the copay does not count toward a person’s Part D deductible or total out-of-pocket spending. CMS Administrator Dr. Mehmet Oz said the program makes costly treatments “more affordable and accessible,” and HHS Medicare director Chris Klomp said it is meant to make access “simpler, more predictable, and more consistent.”

Who qualifies

Eligibility is strict, which may surprise patients who hear that “Medicare covers GLP-1s now.” Medicare.gov says beneficiaries must be 18 or older and meet BMI and health risk criteria when they start therapy.

A person may qualify with a BMI of 35 or higher. Someone with a BMI of 30 to 34.99 may qualify with conditions such as heart failure with preserved ejection fraction, uncontrolled high blood pressure, stage 3a or higher chronic kidney disease, prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease.

A person with a BMI of 27 to 29.99 may qualify with prediabetes, a past heart attack or stroke, or symptomatic peripheral artery disease. A provider must also complete prior authorization when required and certify that the medication is part of a lifestyle program focused on diet and exercise.

Why this could change care

The hopeful part is real. CDC data from August 2021 through August 2023 found that 40.3% of U.S. adults had obesity, including 38.9% of adults aged 60 and older. Obesity usually has a higher risk for stroke, type 2 diabetes, heart attack, coronary heart disease, some cancers, and mobility limitations, which are all deeply relevant to Medicare.

The FDA’s 2024 Wegovy decision helped shift the debate by approving the drug to reduce the risk of heart attack, cardiovascular death and in adults with obesity and cardiovascular disease.

John Sharretts, M.D., a director in the FDA’s Center for Drug Evaluation and Research, said Wegovy became the first weight-loss medication approved to help prevent life-threatening cardiovascular events in that group. For older patients, the story shifts from appearance to risk, function, and years of life lived with less strain.

The access gap

Coverage is not the same as access. KFF estimates that 13.3 million Medicare beneficiaries had obesity or overweight based on 2023 claims or encounter data, but only 3.8 million Part D enrollees met the Bridge eligibility rules.

That is still a large number of people, equal to 8% of Part D enrollees in 2023, but it also shows how narrow the pilot is compared with the size of the need. Some patients will be excluded because they already qualify for GLP-1 coverage under Part D for conditions such as type 2 diabetes or MASH.

Others may meet the medical risk profile but struggle with prior authorization, provider visits, pharmacy processing, or the plain confusion of a new program starting midyear. A $50 copay can open the door, but paperwork can still stand in the hallway.

The cost question

The government is not doing this out of pure sentiment. It is collecting data on use, costs, and outcomes.

KFF estimates that if 10% to 25% of the 3.8 million eligible beneficiaries participate and fill prescriptions each month for the full 18-month Bridge, Medicare costs could reach about $1.3 billion to $3.3 billion, assuming a $245 net monthly cost minus the $50 patient copay.

The Congressional Budget Office estimated in 2024 that broader Medicare coverage of anti-obesity drugs would raise net federal spending by about $35 billion from 2026 to 2034, because direct drug costs would outweigh near-term medical savings.

That fiscal warning does not erase the human case for access. It simply means the pilot is also a budget test dressed in a white coat.

The health-system readiness test

Doctors are also urging care, especially for older adults. Reuters reported that clinicians worry some patients could lose lean muscle and bone density along with fat, raising concerns about frailty, fractures, and medication absorption.

Dr. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital, told Reuters that doctors often advise 1.2 to 1.6 grams of protein per kilogram of body weight daily during weight loss to help preserve muscle.

Dr. John Batsis, a geriatric medicine specialist at the University of North Carolina at Chapel Hill, warned that “access to the drug may expand faster than access to the clinical support needed to use it safely and effectively.”

That is the quiet challenge underneath the excitement: these drugs work best inside a care plan, not as a lonely injection in the fridge.

The 2027 cliff

The most important date after July 1, 2026, may be December 31, 2027. That is when the Bridge is scheduled to end. KFF says it is uncertain how beneficiaries will maintain Medicare coverage for GLP-1 obesity treatment after the pilot unless CMS launches another model or policymakers act.

Reuters quoted Juliette Cubanski, KFF’s Medicare policy program director, saying, “In the short term, we have this program that will be helpful for people,” but it “doesn’t really represent a sustainable approach to longer-term Medicare coverage of drugs used for weight loss.”

For patients who respond well, the cliff is not abstract. It could mean starting a medicine, losing weight, improving health markers, and then facing a coverage gap just as the treatment becomes part of daily life.

What readers can take away

Medicare’s new coverage of obesity drugs is encouraging because it treats obesity care as real care. It is also limited, temporary, and full of fine print. The Obesity Action Coalition told CMS in 2025 that there is strong medical consensus that obesity is a complex chronic disease and argued that people need to have access to safe and effective treatment options.

That is the heart of this moment. The Bridge may help millions of eligible patients stop seeing GLP-1 drugs as medicine for someone richer, younger, or luckier. But the program’s success will depend on more than price.

It will depend on doctors who can guide patients safely, pharmacies that can handle demand, policymakers willing to face the cost honestly, and a health system ready to treat obesity with less blame and more care.

Disclaimer – This list is solely the author’s opinion based on research and publicly available information. It is not intended to be professional advice.

Like our content? Be sure to follow us